Medicare and insurance coverage for skin substitutes, amniotic membrane grafts, and cellular tissue products.
Medicare Part B covers skin substitutes and cellular/tissue-based products (CTPs) for chronic wounds under strict criteria. These advanced biologics can transform wound healing, achieving 95% closure rates in wounds that failed standard treatment. However, coverage requires comprehensive documentation proving medical necessity and failed conventional therapy.
All four requirements must be met:
1. Wound has not healed after 30 days of standard wound care
2. Wound bed is free of necrotic tissue and infection
3. Documentation shows appropriate wound care measures attempted
4. Product is FDA-regulated and on Medicare's approved list
EpiFix, AmnioExcel, Grafix, PuraPly, and other dehydrated amniotic membranes. Medicare covers for diabetic foot ulcers, venous leg ulcers, pressure ulcers (Stage III/IV), and burns. Typical approval: 2-4 applications per wound depending on size. Each application must show measurable improvement.
Cost per application: $200-500 (your 20% after Medicare pays 80%)
Apligraf, Dermagraft, and other bioengineered skin containing living cells. Primarily approved for venous leg ulcers and diabetic foot ulcers. Higher scrutiny and often requires failure of amniotic products first. Limited to specific square centimeter coverage per application.
Cost per application: $300-600 (your 20% coinsurance)
Collagen-based scaffolds like AlloDerm, Integra, and Oasis. Used for deep wounds requiring dermal reconstruction. Coverage for full-thickness wounds with significant tissue loss where standard healing won't provide adequate closure.
Cost varies by product and wound size
Medicare requires exhaustive documentation: (1) Baseline wound photos with measurements showing wound present for 30+ days, (2) Treatment log showing all standard therapies attempted (debridement, offloading, moist wound healing, infection control), (3) Evidence that standard care failed (no size reduction or healing plateau), (4) Current wound bed assessment confirming no necrotic tissue or infection, (5) Medical necessity statement explaining why patient requires cellular product, (6) Comorbid conditions affecting healing (diabetes, vascular disease, immunosuppression). Missing any element results in denial.
Medicare typically approves initial application plus 1-3 additional applications if needed. Each subsequent application requires documentation of improvement from previous application (minimum 10-15% size reduction). If wound hasn't improved after 2-3 applications, Medicare will deny further applications. Maximum application frequency: once every 14 days. Wounds must show continued improvement or coverage stops.
⊗ Insufficient documentation of failed conventional treatment
⊗ Wound contains necrotic tissue or active infection
⊗ Less than 30 days of standard care documented
⊗ No improvement shown between applications
⊗ Product used for unapproved indication
⊗ Missing baseline photos or measurements
Healix360 maintains meticulous documentation to prevent denials and handles all appeals when denials occur.
Original Medicare (Part B) does not require prior authorization, as claims are reviewed after treatment. Medicare Advantage plans, however, typically require prior authorization before skin substitute application. Healix360 manages all authorization requests and works directly with Medicare contractors to help ensure coverage approval.
We immediately appeal denied claims by submitting additional medical documentation and clinical justification. Most denials are overturned on appeal when proper documentation is provided. If an appeal is not successful, you are not billed for the denied service unless you signed an Advance Beneficiary Notice (ABN) acknowledging the possibility of non-coverage prior to treatment.
Medicare does not set a fixed limit on the number of skin substitute applications but expects wounds to show continuous measurable improvement. Typical coverage is for 2–4 applications per wound. Each application must demonstrate progress, generally defined as a minimum 10–15% reduction in wound size. If improvement stalls, Medicare may discontinue coverage and require alternative treatment approaches.
Skilled nursing facilities, assisted living, and home patients—we provide comprehensive onsite care.
Healix360 Advanced mobile wound care specialists connecting patients with regenerative healing solutions. Medicare Part B accepted.
6618 San Fernando Rd Glendale Ca 91201
Copyright © 2026 Healix360.com. All Rights Reserved.
